Detailed Narrative
Strong Q4 FY25 Performance and FY25 Overview
Anupam Rasayan reported a robust Q4 FY25 with consolidated operating revenue of INR500 crores, marking a 24.68% Y-o-Y and 31% Q-o-Q growth. EBITDA for the quarter stood at INR150 crores, up 42.86% Y-o-Y, achieving a 30% margin. For the full fiscal year FY25, consolidated operating revenue was INR1,437 crores, a slight decline of 2.58% Y-o-Y from INR1,475 crores in FY24, while EBITDA remained stable at INR412 crores, with a 29% margin. The company noted a clear recovery in the second half of FY25, particularly in Q4, after a subdued first half due to macro conditions.
Segmental Growth Drivers and Agrochemical Revival
The Pharma and Performance Material segments were key growth drivers. Pharma revenue surged 41% Y-o-Y in Q4 FY25 and an impressive 92% Y-o-Y for the full FY25, contributing 21.9% to total sales. Performance material also saw significant growth, up 83% Y-o-Y in Q4 FY25 and 18% Y-o-Y for FY25, representing 16.6% of Q4 revenue. The agrochemical sector, which faced demand challenges earlier in the year, showed signs of revival in Q4, supported by the ramp-up of a recently launched high-value molecule from a 2022 LOI.
Strategic Market Expansion and New LOIs
The company is expanding its geographical presence, with Japan continuing to be a strong growth market, contributing 17% of sales in Q4 FY25 and projected to exceed 20% in FY26. A significant new LOI was signed with a US-based MNC for a high-performance specialty chemical used in critical power applications, expected to contribute meaningfully and exceed 10% of sales in FY26. This patented Elementium product for EV batteries is seen as a potential 'blockbuster,' with initial volumes starting in 2026 and a long-term revenue potential of $350-400 million over seven years.
Capital Expenditure and Debt Management
Anupam Rasayan completed INR670 crores of planned capex, with two new manufacturing facilities already commercialized and one ready for commercialization, enhancing production capacity. The company anticipates a decline in debt levels, with INR185 crores of long-term debt expected to be settled in FY26 through warrant conversion. Management aims for term debt to be 'practically zero' and working capital days to normalize around 200 days within two years, supported by an operating cash flow of approximately INR140 crores.
Working Capital and Inventory Strategy
Working capital remains a challenge, primarily due to high inventory levels built up in the agro segment during 2023-24 when demand was stronger. With the revival in agro demand, the company expects to liquidate this inventory. Management clarified that the FY25 revenue decline was largely volume-driven, not price-driven, and that raw material price volatility has had minimal impact on final product pricing due to their cost structure and pass-through ability, with RMC being 30-40% of total costing.
Outlook and Long-Term Vision
The company is confident in returning to historical revenue growth rates of 25-30% plus from FY26 onwards, maintaining EBITDA margins in the 26-28% range. The total order book stands at INR14,646 crores, with INR3,100 crores already commercialized. The Elementium product for EV batteries is seen as a potential 'blockbuster,' with initial volumes starting in 2026 and a long-term revenue potential of $350-400 million over seven years, contributing to the company's strategy of deepening presence in high-value markets and geographical diversification.